10-Q: AIXIN LIFE Faces Steep Revenue Drop, Going Concern Doubt

AIXIN LIFE INTERNATIONAL, INC. reports a 61% revenue decline and increased losses, raising substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the six months ended June 30, 2025, decreased by 61% to $859,760 from $2,184,209 in the same period of 2024.
• Net loss for the six months ended June 30, 2025, increased by 38% to $(1,073,213) compared to $(780,383) in the prior year.
• Loss from operations for the six months ended June 30, 2025, increased by 68% to $(1,493,109) from $(890,071) in the prior year.
• Cash and cash equivalents decreased from $62,310 on December 31, 2024, to $29,621 on June 30, 2025.
• Net cash used in operating activities significantly increased to $(1,150,477) for the six months ended June 30, 2025, from $(348,330) in the prior year.
• The company reported a working capital deficit of $(6,423,194) as of June 30, 2025.
• Management explicitly states that these conditions raise substantial doubt about the company's ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified due to limited resources and deficiencies in design or operation.

Sentiment

Score: 2

Explanation: The company exhibits severe financial distress, marked by a 61% revenue decline, a 38% increase in net loss, and a substantial increase in cash used in operations, leading to a stated going concern doubt. While management has a liquidity plan, its success is not assured, and the company faces material weaknesses in internal controls.

Positives

• Non-operating income increased significantly to $420,945 for the six months ended June 30, 2025, primarily due to a gain on disposal of fixed assets.
• Operating expenses decreased by 15% to $1,223,992 for the six months ended June 30, 2025, mainly due to decreased stock-based compensation and depreciation expense.
• Management has developed a liquidity plan that includes continuous cost reductions and sales of higher margin products, alongside seeking loans from related parties and potential equity offerings.

Negatives

• Direct sales revenue decreased by 90% to $51,968 for the six months ended June 30, 2025, attributed to an economic downturn and challenging marketing activities.
• Pharmacy revenue decreased by 87% to $62,407 for the six months ended June 30, 2025, due to economic downturn, marketing challenges, and increased online shopping convenience.
• Hotel revenue decreased by 30% to $193,083 for the six months ended June 30, 2025, impacted by the economic downturn and slowdown in the catering industry.
• Manufacture and sales revenue decreased by 38% to $552,302 for the six months ended June 30, 2025, also due to economic downturn and marketing challenges.
• Cost of sales as a percentage of sales increased in the pharmacy segment (67% vs 31%) and manufacture and sales segment (101% vs 69%), indicating reduced profitability per sale.
• The company's cash and cash equivalents declined significantly, indicating a rapid depletion of liquid assets.
• A substantial working capital deficit of $(6,423,194) highlights severe short-term liquidity issues.
• High customer concentration, with one customer accounting for 44% of total revenue for the six months ended June 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, negative cash flows from operations, and a significant working capital deficit.
• There is no assurance that the management's liquidity plan, including cost reductions, sales of higher margin products, and financing arrangements, will be successfully implemented.
• Failure to successfully implement the liquidity plan could have a material adverse effect on the company's business, results of operations, and financial position.
• Additional issuances of equity or convertible debt securities, if pursued for capital raising, will result in dilution to current shareholders and could cause the common stock price to decrease.
• Additional financing may not be available on acceptable terms, or at all, which could significantly restrict business operations and prevent the company from pursuing new opportunities.
• The company operates in highly competitive industries with an unproven revenue model, and there is no certainty of achieving or sustaining profitability.
• Future operating results are dependent on external factors such as demand for products, competitive landscape, and management's ability to effectively manage business growth.
• Operations in the PRC are subject to significant political, economic, and legal environment risks, including changes in governmental policies, anti-inflationary measures, and currency conversion restrictions.
• The RMB is not freely convertible into foreign currencies, which may affect the company's ability to remit funds abroad.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to accurately record, process, summarize, and report financial information.

Future Outlook

Management believes its liquidity plan, which includes continuous cost reductions, sales of higher margin products, and raising cash through related party loans and potential equity offerings, should provide sufficient liquidity for the next twelve months. The company intends to seek additional opportunities in China's growing healthcare market, including expanding its product line through internal research and third-party acquisitions, acquiring more pharmacies and retail outlets, and potentially operating nursing homes and clinics. However, the company acknowledges that its business model is unproven, and there is no assurance of achieving or sustaining profitability.

Management Comments

• "Management believes that it has developed a liquidity plan... that, if executed successfully, should provide sufficient liquidity to meet the Company’s obligations as they become due for a reasonable period of time, and allow the development of its core business."
• "We intend to look for additional opportunities to profit from the growing healthcare market in China."
• "We intend to build a reputation as a provider of premium health and wellness products that seeks to improve our customers health and well-being."
• "Our objective is to offer a broad and deep mix of products for consumers interested in living well, whether they are looking to treat a health-related issue or simply maintain their overall wellness."

Industry Context

The company operates in the health and wellness market in China, targeting the growing middle class. It aims to address health issues like obesity, hypertension, and insomnia, which are increasing due to evolving lifestyles, work pressures, and dietary changes. The company competes with a diverse range of players, including food, drug, and mass channel retailers, specialty stores, independent vitamin and supplement shops, and online retailers, by offering proprietary and third-party products through an omni-channel distribution network.

Corporate Governance

Related Party Transactions

• Accounts receivable from related parties totaled $440,824 as of June 30, 2025, primarily from entities controlled by Mr. Quanzhong Lin (Chairman, CEO, major shareholder) or Huiliang Jiao (Director).
• Sales revenue to related parties amounted to $207,228 for the three months and $385,937 for the six months ended June 30, 2025.
• Purchases from related parties amounted to $16,922 for the three months and $25,717 for the six months ended June 30, 2025.
• Accounts payable to related parties totaled $61,857 as of June 30, 2025.
• Prepaid expenses to related parties totaled $8,138 as of June 30, 2025.
• Unearned revenue from a related party (Shengcaofeng Health Industry (Yunnan) Co., Ltd, owned by Huiliang Jiao) was $188,362 as of June 30, 2025.
• Due from related parties totaled $3,350 as of June 30, 2025.
• Due to related parties totaled $4,541,916 as of June 30, 2025, with a significant portion owed to Mr. Quanzhong Lin ($4,357,059).
• Amounts due from and to related parties are for working capital purposes, payable on demand, and bear no interest.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings and a high probability of further stock price decline due to severe financial deterioration and going concern doubt.
• Creditors, particularly related parties, bear increased risk due to the company's substantial working capital deficit and explicit going concern warning.
• Employees may face uncertainty regarding job security or compensation if cost reduction measures become more aggressive or if the company's financial situation does not improve.
• Customers might experience potential disruptions in product availability or service quality if the company's operational and financial challenges persist.

Next Steps

• Implement liquidity plan, including continuous cost reductions and sales of higher margin products.
• Pursue financing arrangements through related party loans and potential equity offerings.
• Address material weaknesses in internal control over financial reporting by designating individuals responsible for identifying reportable developments and implementing remedial procedures.
• Explore expanding product line through internal research and acquiring complementary products from third parties.
• Explore acquiring additional pharmacies and other retail outlets.
• Explore operating nursing homes and possibly clinics which provide medical care to clients.

Key Dates

Recommendation

The company exhibits severe financial distress, marked by a 61% revenue decline, a 38% increase in net loss, and a substantial increase in cash used in operations, leading to a stated going concern doubt. The significant working capital deficit of over $6.4 million and identified material weaknesses in internal controls indicate a high level of operational and financial risk. While management outlines a liquidity plan, its success is uncertain, and any potential capital raise would likely result in significant shareholder dilution. The current financial trajectory suggests a high probability of further value erosion, making it a strong sell.

Keywords

Healthcare, Wellness, Nutritional Products, Pharmacies, Hotel Management, Manufacturing, China Market, SEC Filing, 10-Q, Financial Performance, Going Concern, Liquidity, Revenue Decline, Net Loss, Operating Loss, Cash Flow, Related Party Transactions, Internal Controls, Risk Factors